Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Advocacy groups from 30 countries are urging Merck to create a global access strategy for its once-a-month HIV prevention ...

Sanofi has replaced chief executive Paul Hudson with the head of German drugmaker Merck KGaA, after the French drugmaker ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s MRK Keytruda (pembrolizumab) and ...

But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...

New KEYTRUDA indications are expected to preserve Merck's top line. Click here to read why MRK stock remains a great buy upon ...

In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO ...

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per ...

Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total ...

There will be a public meeting regarding the closure of the Cherokee Pharmaceuticals hazardous waste facility along the ...